Dienogest is an oral progestin used for the treatment of endometriosis as monotherapy or contraception in combination with ethinylestradiol. Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone.
- Mechanism
- Curator reviewed · 4 references
Dienogest acts as an agonist at the progesterone receptor (PR) with weak affinity that is comparable to that of progesterone but has a very potent progestagenic effect in the endometrium, causing endometrial atrophy after prolonged use. It promotes antiproliferative, immunologic and antiangiogenic effects on endometrial tissue. Dienogest reduces the level of endogenous production of oestradiol and thereby suppressing the trophic effects of oestradiol on both the eutopic and ectopic endometrium. Continous administration of dienogest results in hyperprogestogenic and moderately hypoestrogenic endocrine environment, which causes initial decidualization of endometrial tissue. It is an antagonist at androgen receptors, improve androgenic symptoms such as acne and hirsutism.
- Primary indication
- Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.Curator reviewed · 4 structured indications
- Formula / weight
- C20H25NO2 · 311.425 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2010
- Also known as
- Dienogestril · Endometrion
- Code names
- BAY 86-5258 · M 18575 · MJR-35 · STS 557 · ZK 37659
- Brand names
Resolves to
AZFLJNIPTRTECV-FUMNGEBKSA-NSMILES[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]What you can answer from here — as of May 03, 2025
Which drugs share a target with Dienogest, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account